Thermo Fisher CDR (CAD Hedged)

Thermo Fisher CDR (CAD Hedged)

TMO · NEO · Healthcare / Diagnostics & Research

24.80CAD-0.18 (-0.72%)

Price History

Full chart

Market Stats

Previous Close24.98
Open24.75
Day Range24.75 – 24.80
52-Week Range15.71 – 24.23
Volume901
Market Cap323.09B
P/E (TTM)36.03
Forward P/E22.57
EPS0.65
Dividend Yield0.30%
Beta0.90
50-Day Avg20.92
200-Day Avg17.75

About

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Marc N. Casper
  • Employees125.00K
  • Headquarters168 Third Avenue, Waltham, MA, United States, 02451, Canada
  • Websitehttps://www.thermofisher.com

Leadership

  • Mr. Marc N. CasperChairman, President & CEO · b. 1968
  • Mr. Stephen WilliamsonSenior VP & CFO · b. 1967
  • Mr. Michel LagardeExecutive VP & COO · b. 1975
  • Mr. Frederick M. LoweryExecutive VP and President of Laboratory Product & BioProduction · b. 1971
  • Mr. Gianluca PettitiExecutive VP and President of Life Science, Diagnostics & Applied · b. 1979
  • Mr. Joseph R. HolmesVP & Chief Accounting Officer · b. 1979
  • Mr. Ryan J. SnyderSenior VP & Chief Information Officer
  • Dr. Karen E. Nelson Ph.D.Chief Scientific Officer
  • Mr. Rafael TejadaVice President of Investor Relations
  • Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue39.21B44.91B42.86B42.88B44.56B
Growth (%)-+14.55%-4.58%+0.05%+3.91%
Cost of Revenue19.57B25.94B25.76B25.18B26.32B
Gross Profit19.64B18.97B17.10B17.70B18.24B
Gross Margin50.08%42.24%39.90%41.28%40.93%
Operating Expense9.41B10.46B9.78B9.98B10.13B
Operating Income10.22B8.51B7.32B7.72B8.11B
Operating Margin26.08%18.94%17.08%18.00%18.20%
EBITDA-11.94B11.08B11.54B11.51B
EBITDA Margin-26.59%25.85%26.90%25.83%
Net Income7.72B6.95B6.00B6.33B6.70B
Net Income Margin19.70%15.47%13.99%14.77%15.05%
R&D1.41B1.47B1.34B1.39B1.40B
R&D as % of Total Revenue3.59%3.28%3.12%3.24%3.14%
Interest Expense536.00M726.00M1.38B1.39B1.42B
Interest Expense % of Total Revenue1.37%1.62%3.21%3.24%3.18%

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets95.12B97.15B98.73B97.32B110.34B
Total Liabilities54.15B53.01B51.88B47.65B56.81B
Total Equity40.79B43.98B46.73B49.59B53.41B
Cash4.48B8.52B8.08B4.01B9.85B
Net Debt30.39B25.96B26.84B27.27B29.53B

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow9.31B9.15B8.41B8.67B7.82B
Financing Cash Flow6.58B-2.81B-3.62B-6.79B1.80B
Capital Expenditure2.52B2.24B1.48B1.40B1.52B
Free Cash Flow6.79B6.91B6.93B7.27B6.29B
Dividends Paid395.00M455.00M523.00M583.00M636.00M
FCF to OCF72.91%75.50%82.41%83.85%80.49%
Dividend Paid to FCF5.82%6.58%7.55%8.02%10.11%

Key Statistics & Ratios

Market Cap323.09B
Enterprise Value400.18B
Trailing P/E36.03
Forward P/E22.57
PEG Ratio1.85
Price / Sales7.39
Price / Book4.35
EPS0.65
Book Value187.12
Revenue (TTM)43.74B
Gross Profit (TTM)18.10B
EBITDA10.84B
Profit Margin15.02%
Operating Margin19.28%
Return on Equity13.12%
Return on Assets4.94%
Shares Outstanding13.80B
Shares Float374.80M
Beta0.90
Dividend Yield0.30%
Dividend Rate0.06
Payout Ratio9.30%

Dividends

20263×
0.02Sep 15, 20260.02Jun 15, 20260.02Mar 13, 2026
20254×
0.02Dec 15, 20250.02Sep 15, 20250.02Jun 13, 20250.02Mar 14, 2025
20244×
0.01Dec 13, 20240.01Sep 13, 20240.01Jun 14, 20240.01Mar 14, 2024